The Impact of Genetic Polymorphism on the Echocardiographic Parameters and Cardiac Fibrosis Markers in Response to Empagliflozin Treatment Among Patients With Heart Failure
Active, not recruitingOBSERVATIONAL
Enrollment
92
Participants
Timeline
Start Date
July 30, 2023
Primary Completion Date
July 30, 2025
Study Completion Date
October 1, 2025
Conditions
Heart Failure
Trial Locations (1)
11315
Ain shams university, Cairo
All Listed Sponsors
lead
Ain Shams University
OTHER
NCT06503601 - The Impact of Genetic Polymorphism on the Echocardiographic Parameters and Cardiac Fibrosis Markers in Response to Empagliflozin Treatment Among Patients With Heart Failure | Biotech Hunter | Biotech Hunter